VoxelMatters3h
KeratOprinter aims to restore vision for millions with bioprinting technology
Explore the KeratOPrinter project, an innovative solution to corneal shortages using advanced bioprinting technology.
Study finds eye injury previously thought irreversible was cured in human trials
The study was led by Harvard Medical School and Massachusetts Eye and Ear researchers and surgeons. The researchers reported ...
BioPharma Dive5d
Alcon buys majority stake in IPO-seeking cell therapy startup Aurion
The share acquisition is the latest twist in a dispute between Alcon and fellow Aurion shareholder Deerfield Management over ...
EMBO Press5d
HDAC6 deacetylates ENKD1 to regulate mitotic spindle behavior and corneal epithelial homeostasis
HDAC6 is upregulated in corneal diseases and causes ENKD1 deacetylation at lysine 98. Deacetylation of ENKD1 blocks its ...
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease ...
Fierce Biotech5d
Alcon gains upper hand in Aurion power struggle via majority stake, removing CEO
Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a ...
Business Wire6d
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority interest in Aurion Biotech ...
Morningstar6d
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
Leverages Alcon’s global scale with Aurion’s cell therapy expertise to accelerate U.S. Phase 3 development in fall of 2025 Aurion’s lead asset received Breakthrough Therapy Designation and ...